Isis Pharmaceuticals (ISIS): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Isis Pharmaceuticals ( ISIS) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.5%. By the end of trading, Isis Pharmaceuticals rose $1.59 (4.3%) to $38.14 on average volume. Throughout the day, 1,558,489 shares of Isis Pharmaceuticals exchanged hands as compared to its average daily volume of 1,479,400 shares. The stock ranged in a price between $36.21-$38.33 after having opened the day at $36.95 as compared to the previous trading day's close of $36.55. Other companies within the Drugs industry that increased today were: Echo Therapeutics ( ECTE), up 72.9%, Zalicus ( ZLCS), up 29.8%, Alimera ( ALIM), up 19.1% and Veracyte ( VCYT), up 13.2%.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Isis Pharmaceuticals has a market cap of $4.2 billion and is part of the health care sector. Shares are up 246.6% year to date as of the close of trading on Monday. Currently there are 3 analysts that rate Isis Pharmaceuticals a buy, 2 analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Isis Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

On the negative front, Mast Therapeutics ( MSTX), down 39.9%, Prima Biomed ( PBMD), down 16.0%, Genvec ( GNVC), down 9.5% and Ariad Pharmaceuticals ( ARIA), down 8.8% , were all laggards within the drugs industry with Shire ( SHPG) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Stocks Search for Direction as Trump Comments Lead to Worries Over China Talks

Stocks Search for Direction as Trump Comments Lead to Worries Over China Talks

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

Italy's President Gives Mandate For Anti-European Government in Rome

Italy's President Gives Mandate For Anti-European Government in Rome